Swedish biopharmaceutical company Xbrane Biopharma AB (Xbrane) (STO:XBRANE) on Friday reported a loss of SEK32.4m, or SEK2.24 per share, for the third quarter of 2019, from July 2019 to September 2019.
This was a decline over profit of SEK 60.1m, or EPS of SEK9.49, in the third quarter of 2019.
Revenues for the quarter amounted to SEK0.0m, a decline over SEK2.4m in previous third quarter.
Also, Xbrane added that it has secured financing for the Xplore study up until top-line data is received from all patients
In addition, a rights issue that began in the second quarter of 2019 was completed and brought in SEK91.1m to the company, before transaction costs.
Xbrane develops and produces biosimilars. It has a patented protein production platform for development of biosimilars.
(EUR1.00=SEK10.66)
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation